Nachrichten und Videos - NOVARTIS N

Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a...

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) PR Newswire EAST HANOVER, N.J., April 2, 2025 Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P<0.0001) vs....

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) PR Newswire EAST HANOVER, N.J., March 20, 2025 Phase III study showed sustained proteinuria reduction at one year with favorable safety 1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G 1-3 C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney...

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) PR Newswire EAST HANOVER, N.J., Feb. 28, 2025 Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx ® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key...

Blackstone Life Sciences (BXLS) et Anthos Therapeutics Inc. (« Anthos » ou la « Société »), une société biopharmaceutique transformatrice au stade clinique spécialisée dans le développement de thérapies innovantes pour le traitement des maladies cardiométaboliques, ont annoncé aujourd’hui que BXLS a conclu avec Novartis un accord portant sur l’acquisition d’Anthos pour un montant pouvant atteindre 3,1 milliards USD. Fondée par Blackstone Life Sciences et Novartis en 2019,...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and...

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Sonstiges Novartis Deutschland entscheidet sich für neuen Bürokomplex im Herzen Münchens 05.02.2025 / 09:06 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. MEDIENMITTEILUNG Novartis Deutschland entscheidet sich für neuen Bürokomplex im Herzen Münchens Bekenntnis zum Innovationsstandort München und zur Wirtschaftsregion Bayern Fortsetzung des Netzwerkmodells mit direkter Anbindung an das öffentliche...

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical...

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Sonstiges Novartis Deutschland weiht neuen Firmensitz am Traditionsstandort Nürnberg ein und setzt auf Wirtschaftsregion Bayern 04.12.2024 / 11:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. MEDIENMITTEILUNG Novartis Deutschland weiht neuen Firmensitz am Traditionsstandort Nürnberg ein und setzt auf Wirtschaftsregion Bayern Bezug neuer Büroräume im Güterwerk des Kohlenhof-Areals steht für...

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR Newswire WARREN, N.J., Dec. 2, 2024 - PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales - - Novartis will assume global development, manufacturing and commercial responsibilities following...

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate PR Newswire BOSTON, Nov. 18, 2024 Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON , Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR Newswire EAST HANOVER, N.J., Oct. 18, 2024 If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ® (ribociclib) in combination with an aromatase inhibitor 1 Recommendation is based on the Phase III...

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Sonstiges Deutsches Krebsforschungszentrum und Novartis Deutschland initiieren Gesprächsrunde zu Erfolgsfaktoren für Innovationsstandort Deutschland 11.10.2024 / 10:04 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. MEDIENMITTEILUNG Deutsches Krebsforschungszentrum und Novartis Deutschland initiieren Gesprächsrunde zu Erfolgsfaktoren für Innovationsstandort Deutschland Austausch zwischen Vertretern von...

NORTHAMPTON, MA / ACCESSWIRE / August 26, 2024 / Common Impact As seen on commonimpact.org Charlotte Rocker and Dan Barnett might come from different worlds, but they share a common passion for making a difference. Charlotte, a dynamic product strategy lead at Novartis , is passionate about bringing innovative medicines to patients in need. On the other hand, Dan is a dedicated leader in the nonprofit sector, steering Students 2 Science (S2S) as the Chief Development officer to bring STEM...

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) PR Newswire East Hanover, N.J., Aug. 7, 2024 Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001) 1 Fabhalta is an inhibitor of the alternative complement...

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Kooperation Neues Versorgungskonzept zur Prävention von Herz-Kreislauf-Ereignissen: Novartis und das Universitätsklinikum Schleswig-Holstein kooperieren beim Aufbau eines Lipid-Netzwerks 11.07.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. MEDIENMITTEILUNG Neues Versorgungskonzept zur Prävention von Herz-Kreislauf-Ereignissen: Novartis und das Universitätsklinikum Schleswig-Holstein...

Department of Health - Abu Dhabi and Novartis to Partner to Advance Genomics Research in Oncology and Beyond PR Newswire ABU DHABI, UAE, June 7, 2024 ABU DHABI , UAE, June 7, 2024 /PRNewswire/ -- At BIO 2024 International Convention , the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE , a global pharmaceutical company. Under the terms of the MoU, the entities will work...

EQS-News: Novartis Pharma GmbH / Schlagwort(e): Sonstiges Sozialer Roboter ‚Navel‘ gewinnt Digitalen Gesundheitspreis von Novartis 07.06.2024 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Sozialer Roboter ‚Navel‘ gewinnt Digitalen Gesundheitspreis von Novartis Das Gewinnerprojekt der navel robotics GmbH unterstützt Pflegepersonal bei der sozialen Betreuung von Pflegeheimbewohner*innen Platz 2 sicherte sich die digitale Plattform für...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire EAST HANOVER, N.J., May 25, 2024 In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks 1 Endothelin A (ETA) receptor activation contributes to elevated...

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo PR Newswire EAST HANOVER, N.J., May 25, 2024 Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3 Fabhalta showed a favorable safety profile with no...